Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACI-19764 (NLRP3 Inhibitor) in Neurological disorder. The expected timing is based on the latest available company guidance and may change.
11/04/25:- Small molecule NLRP3 inhibitor ACI-19764 planned IND/CTA filing expected in Q4 2025. 02/24/26:- First participant dosed in Ph1 HV trial. Initial Ph1 data expected H2 2026. 03/13/26:- Phase 1 HV trial (NCT07463196) ongoing; first participants dosed; initial results expected H2 2026. 04/30/26:- SAD/MAD Ph1 HV trial ongoing; results expected H2 2026. 07/07/26:- AAIC 2026 poster July 12 highlights preclinical NLRP3 efficacy; Ph1 data still expected H2 2026. 08/05/26:- Ph1 SAD/MAD results near-term; Ph1b hsCRP results expected H2 2026. 08/20/26:- Positive interim Ph1 SAD/MAD safety and CSF penetration. Ph1b hsCRP cohort results expected before year-end; full results H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.